Moreover, we are not aware of any other study in which p53, p16 and pRb expression has been characterised in the same cohort of pTa and pT1 bladder cancers, and assessed collectively in relation to disease progression. The gene discussed is CDKN2A; the disease is urinary bladder cancer.